Natixis Protagonist Therapeutics, Inc Transaction History
Natixis
- $22 Billion
- Q2 2025
A detailed history of Natixis transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Natixis holds 42,040 shares of PTGX stock, worth $3.22 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
42,040Holding current value
$3.22 Million% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
297Shares Held
67.3MCall Options Held
290KPut Options Held
318K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$473 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$441 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$441 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$334 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$249 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $3.76B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...